Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Stock Short Interest Declines 71.6%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 200 shares, a decline of 71.6% from the September 30th total of 705 shares. Based on an average daily trading volume, of 4,414 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Santen Pharmaceutical Stock Performance

SNPHY opened at $10.78 on Friday. The company’s 50-day simple moving average is $11.16 and its two-hundred day simple moving average is $11.49. Santen Pharmaceutical has a 52-week low of $9.22 and a 52-week high of $13.93.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company focused on ophthalmology. The company researches, develops, manufactures and markets prescription medicines and other products used to diagnose and treat eye diseases.

Its product portfolio includes ophthalmic treatments for conditions such as glaucoma, dry eye, allergic eye disease, ocular infections and retinal disorders. Santen also develops therapies for other vision-related conditions and provides products for eye-care professionals and patients.

Founded in 1890 and headquartered in Osaka, Japan, Santen serves patients and medical professionals through operations and commercial activities in Japan and international markets, including parts of Asia, Europe and other regions.